Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2759083 | 0.93 | KMT2A (0.69) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL2759053 | 0.84 | LMNA (0.59) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL3893912 | 0.84 | KMT2A (0.56) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL1234089 | 0.82 | KMT2A (0.57) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL2759006 | 0.82 | KMT2A (0.57) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL2759017 | 0.81 | KMT2A (0.59) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL3273448 | 0.78 | AOC3 (0.47) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL2759021 | 0.77 | KMT2A (1.00) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL2759015 | 0.77 | SMN1; SMN2 (0.51) | KMT2ASMN1; SMN2LMNATP53ATM | |
| SCHEMBL673181 | 0.76 | CYP19A1 (0.59) | LMNACYP19A1SLC6A2SLC6A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828332-B2 | Non-peptide BDNF neurotrophin mimetics | PharmatorophiX, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828332-B2 | Non-peptide BDNF neurotrophin mimetics | PharmatorophiX, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828330-B2 | Non-peptide BDNF neurotrophin mimetics | PHARMATROPHIX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828330-B2 | Non-peptide BDNF neurotrophin mimetics | PHARMATROPHIX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX, INC. | 2012-01-05 | — | — | US | disclosed |
| WO-2011150347-A2 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | PHARMATROPHIX (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023990-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | KMT2A 3890/4885SMN1; SMN2 34/4885LMNA 3046/4885 |
| US-20120004310-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | KMT2A 3890/4885SMN1; SMN2 34/4885LMNA 3046/4885 |
| US-20160046559-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | NTRK2, BDNF, NTRK1 | KMT2A 3852/4885SMN1; SMN2 47/4885LMNA 2805/4885 |
| US-20140296343-A1 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS | BDNF, NTRK2, NGF | KMT2A 3890/4885SMN1; SMN2 34/4885LMNA 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.